| Abstract |
【Abstract】Objective To explore the effect of S-adenosylmethionine in adjuvant treatment of chronic hepatitis B patients with depression. Methods Ninety-three patients with chronic hepatitis B and depression admitted to our department from August 2018 to August 2020 were selected and randomly divided into two groups. 46 cases in the control group were given conventional treatment, and 47 cases in the observation group were treated with adjuvant S-adenosylmethionine, The liver function indicators (allanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), total bile acid (TBA) levels before and after treatment), laboratory indicators (treatment Serum brain-derived nerve growth factor (BDNF), norepinephrine (NE), 5-hydroxytryptamine (5-HT) levels before and after), mental state (SDS score, SAS score before and after treatment), and adverse reactions between two group were compared. Results After treatment, the ALT, AST, TBIL, TBA indexes and SDS and SAS scores of the two groups were lower than those before treatment, and the observation group was lower than that of the control group (P<0.05). After treatment, the levels of BDNF, NE and 5-HT in the two groups were higher than before treatment, and the observation group was higher than the control group (P<0.05). The incidence of adverse reactions in the observation group was 4.26%, and the incidence of adverse reactions in the control group was 2.17% (P>0.05). Conclusion The effect of S-adenosylmethionine in adjuvant treatment of patients with chronic hepatitis B combined with depression is satisfactory, liver function and laboratory indicators have been improved, mental state has improved significantly, and the safety factor is high.
|